These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. Girotti F; Carella F; Scigliano G; Grassi MP; Soliveri P; Giovannini P; Parati E; Caraceni T J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):848-52. PubMed ID: 6147393 [TBL] [Abstract][Full Text] [Related]
4. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965 [TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia. Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide. Gracey DJ; Bell R; King DJ; Trimble KM; McDermott BJ Pharmacol Biochem Behav; 1998 Apr; 59(4):1053-9. PubMed ID: 9586867 [TBL] [Abstract][Full Text] [Related]
7. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Leonard DP; Kidson MA; Brown JG; Shannon PJ; Taryan S Aust N Z J Psychiatry; 1975 Jun; 9(2):115-8. PubMed ID: 125578 [TBL] [Abstract][Full Text] [Related]
8. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Cann PA; Rovati LC; Smart HL; Spiller RC; Whorwell PJ Ann N Y Acad Sci; 1994 Mar; 713():449-50. PubMed ID: 8185213 [No Abstract] [Full Text] [Related]
9. Clinical evaluation of amantadine and haloperidol in Huntington's chorea. Saran BM; Klein MS; Benay EM J Clin Psychiatry; 1980 Jun; 41(6):221. PubMed ID: 6445900 [No Abstract] [Full Text] [Related]
10. [Treatment of chorea (author's transl)]. Murai Y; Yoshida M; Yanagisawa N Rinsho Shinkeigaku; 1977 Dec; 17(12):811-5. PubMed ID: 24511 [No Abstract] [Full Text] [Related]
11. Proglumide as a morphine adjunct in cancer pain management. Bernstein ZP; Yucht S; Battista E; Lema M; Spaulding MB J Pain Symptom Manage; 1998 May; 15(5):314-20. PubMed ID: 9654837 [TBL] [Abstract][Full Text] [Related]
12. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]. Giménez-Roldán S; Mateo D Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679 [TBL] [Abstract][Full Text] [Related]
13. Proglumide, a cholecystokinin receptor antagonist, exacerbates beta, beta'-iminodipropionitrile-induced dyskinetic syndrome in rats. Tariq M; Khan HA; Rehana Z; Al Moutaery K; Al Deeb S Neurotoxicol Teratol; 1998; 20(5):571-9. PubMed ID: 9761597 [TBL] [Abstract][Full Text] [Related]
14. Platelet dopamine uptake in Huntington's chorea and Gilles de la Tourette's syndrome: effect of haloperidol. Butterworth RF; Gonce M; Barbeau A Can J Neurol Sci; 1977 Nov; 4(4):285-8. PubMed ID: 145893 [TBL] [Abstract][Full Text] [Related]
15. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461 [TBL] [Abstract][Full Text] [Related]
16. Plasma homovanillic acid and prolactin in Huntington's disease. Markianos M; Panas M; Kalfakis N; Vassilopoulos D Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471 [TBL] [Abstract][Full Text] [Related]